Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

USA - NASDAQ:LXEO - US52886X1072 - Common Stock

10.01 USD
+0.58 (+6.15%)
Last: 10/31/2025, 8:00:01 PM
10.01 USD
0 (0%)
After Hours: 10/31/2025, 8:00:01 PM
Fundamental Rating

2

Overall LXEO gets a fundamental rating of 2 out of 10. We evaluated LXEO against 534 industry peers in the Biotechnology industry. The financial health of LXEO is average, but there are quite some concerns on its profitability. LXEO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXEO has reported negative net income.
In the past year LXEO has reported a negative cash flow from operations.
In the past 5 years LXEO always reported negative net income.
In the past 5 years LXEO always reported negative operating cash flow.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LXEO has a Return On Assets (-64.85%) which is in line with its industry peers.
LXEO has a Return On Equity of -82.60%. This is comparable to the rest of the industry: LXEO outperforms 51.87% of its industry peers.
Industry RankSector Rank
ROA -64.85%
ROE -82.6%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, LXEO has more shares outstanding
Compared to 1 year ago, LXEO has an improved debt to assets ratio.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

LXEO has an Altman-Z score of 6.78. This indicates that LXEO is financially healthy and has little risk of bankruptcy at the moment.
LXEO's Altman-Z score of 6.78 is fine compared to the rest of the industry. LXEO outperforms 75.84% of its industry peers.
LXEO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, LXEO perfoms like the industry average, outperforming 46.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.78
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

LXEO has a Current Ratio of 4.43. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
LXEO has a Current ratio of 4.43. This is comparable to the rest of the industry: LXEO outperforms 49.44% of its industry peers.
LXEO has a Quick Ratio of 4.43. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.43, LXEO perfoms like the industry average, outperforming 50.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 4.43
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

LXEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.70%, which is quite impressive.
EPS 1Y (TTM)77.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.51% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.47%
EPS Next 2Y14.6%
EPS Next 3Y8.41%
EPS Next 5Y14.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.6%
EPS Next 3Y8.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (10/31/2025, 8:00:01 PM)

After market: 10.01 0 (0%)

10.01

+0.58 (+6.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-13 2025-11-13/bmo
Inst Owners80.84%
Inst Owner Change0.08%
Ins Owners0.5%
Ins Owner Change1.74%
Market Cap697.00M
Revenue(TTM)N/A
Net Income(TTM)-114172000
Analysts87.14
Price Target21.29 (112.69%)
Short Float %11.31%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.21%
Min EPS beat(2)-23.91%
Max EPS beat(2)13.49%
EPS beat(4)2
Avg EPS beat(4)-8.43%
Min EPS beat(4)-28.59%
Max EPS beat(4)13.49%
EPS beat(8)4
Avg EPS beat(8)-50.48%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.77%
PT rev (3m)9.87%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)9%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)4.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.04
P/tB 5.04
EV/EBITDA N/A
EPS(TTM)-3.26
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.85%
ROE -82.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 4.43
Altman-Z 6.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.25%
EPS Next Y16.47%
EPS Next 2Y14.6%
EPS Next 3Y8.41%
EPS Next 5Y14.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.8%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-57.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.53%
OCF growth 3YN/A
OCF growth 5YN/A

LEXEO THERAPEUTICS INC / LXEO FAQ

What is the fundamental rating for LXEO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LXEO.


What is the valuation status for LXEO stock?

ChartMill assigns a valuation rating of 0 / 10 to LEXEO THERAPEUTICS INC (LXEO). This can be considered as Overvalued.


What is the profitability of LXEO stock?

LEXEO THERAPEUTICS INC (LXEO) has a profitability rating of 1 / 10.


What is the financial health of LEXEO THERAPEUTICS INC (LXEO) stock?

The financial health rating of LEXEO THERAPEUTICS INC (LXEO) is 5 / 10.